Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Burkitt Lymphoma 10Recurrence 9Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Neoplasm, Residual 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × tisagenlecleucel × Clear all
NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Novartis

Phase 1 Terminated
10 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡